Mode
Text Size
Log in / Sign up
Phase 3 N=331 Randomized Quadruple-blind Treatment

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

ANCA-Associated Vasculitis

Enrolled (actual)
331
Serious AEs
43.6%
Results posted
Sep 2022
Primary outcome: Primary: Percentage of Subjects Achieving Disease Remission at Week 26 — 70.1; 72.3 percentage of participants — p=< 0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Avacopan (Drug); Prednisone (Drug); Cyclophosphamide (Drug); Rituximab (Biological); Azathioprine (Drug)
Age
Pediatric, Adult, Older Adult · 12+ yrs
Sex
All
Sponsor
Amgen
Primary completion
Sep 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Subjects Achieving Disease Remission at Week 26
70.1; 72.3 < 0.0001 sig
PRIMARY
Percentage of Subjects Achieving Sustained Disease Remission at Week 52
54.9; 65.7 < 0.0001 sig
SECONDARY
Subject Incidence of Treatment-emergent SAEs, AEs, and Withdrawals Due to AEs
161; 164; 2139; 1779; 74; 70
SECONDARY
Glucocorticoid-induced Toxicity as Measured by Change From Baseline Over the First 26 Weeks in the GTI
36.6; 25.7; 56.6; 39.7; 23.2; 9.9
SECONDARY
Percentage of Participants With BVAS of 0 at Week 4, Regardless of Whether the Subjects Received Glucocorticoids During This Period of Time and Based on Assessment by the Blinded AC
68.9; 62.7
SECONDARY
Change From Baseline Over 52 Weeks in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36v2 and EQ-5D-5L VAS and Index
1.344; 4.445; 2.626; 4.980; 1.88; 7.31
SECONDARY
Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving Remission at Week 26 in the Study
12.2; 7.5
SECONDARY
Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving BVAS=0 at Any Time During the Treatment Period
21.0; 10.1
SECONDARY
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Change in eGFR From Baseline Over 52 Weeks
2.9; 5.8; 4.1; 7.3
SECONDARY
In Subjects With Renal Disease and Albuminuria at Baseline (Based in the BVAS Renal Component), the Percent Change in UACR From Baseline Over 52 Weeks
0; -40; -70; -63; -77; -74
SECONDARY
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), the Percent Change in Urinary MCP-1:Creatinine Ratio From Baseline Over 52 Weeks
-64; -67; -71; -73
SECONDARY
Change in the VDI From Baseline Over 52 Weeks, Including the Week 26 and Week 52 Time Points
0.97; 1.06; 1.15; 1.17
SECONDARY
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (1/5)
-5.69; -5.94; -5.54; -5.62; -5.10; -5.24
SECONDARY
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (2/5)
0.07; 0.07; 0.05; 0.07; -0.01; -0.00
SECONDARY
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (3/5)
0.226; 0.252; 0.244; 0.279
SECONDARY
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (4/5)
1.07; 1.10; 1.20; 1.27
SECONDARY
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Hematology (5/5)
2.6; 2.7; 3.0; 3.2
SECONDARY
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (1/2)
2.3; -6.1; -8.6; -10.7; -0.6; -3.9
SECONDARY
Change From Baseline and Shifts From Baseline in All Safety Laboratory Parameters - Serum Chemistry (2/2)
-0.105; -0.195; -0.200; -0.244; -9.4; -11.0
SECONDARY
Change From Baseline in Vital Signs (1/5)
-2.5; -2.6; -2.4; -1.0; 2.7; 0.5
SECONDARY
Change From Baseline in Vital Signs (2/5)
2.2; 0.9; -1.3; -0.3
SECONDARY
Change From Baseline in Vital Signs (3/5)
-0.03; -0.11; 0.04; -0.11
SECONDARY
Change From Baseline in Vital Signs (4/5)
3.33; 1.93; 3.27; 2.59
SECONDARY
Change From Baseline in Vital Signs (5/5)
1.13; 0.67; 1.12; 0.94
SECONDARY
Number of Subjects With Clinically Significant ECG Changes From Baseline
8; 12
SECONDARY
Number of Subjects Where a Relationship Between Avacopan/Placebo, Glucocorticoid Use, Cyclophosphamide, Rituximab, and Azathioprine or Mycophenolate Use to an AE Was Determined by the Investigator
103; 100; 131; 107; 30; 31
SECONDARY
Certain Safety Endpoints of Interest: Infections, Hepatic System Abnormalities, WBC Count Decreases, and Hypersensitivity
124; 113; 25; 22; 10; 12
SECONDARY
Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study
33; 16

Summary

The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis
  • Male and female subjects, aged at least 18 years, with newly-diagnosed or relapsed associated vasculitis (AAV) where treatment with cyclophosphamide or rituximab is needed; where approved by Regulatory Agencies, adolescents (12-17 year old) may be enrolled
  • Use of adequate contraception
  • Positive test for anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO)
  • At least 1 major item, or at least 3 non-major items, or at least the 2 renal items of proteinuria and hematuria on Birmingham Vasculitis Activity Score (BVAS)
  • Estimated glomerular filtration rate ≥15 mL/minute/1.73 m^2 at screening

Exclusion Criteria

  • Pregnant or breast-feeding
  • Alveolar hemorrhage requiring pulmonary ventilation support at screening
  • Any other known multi-system autoimmune disease
  • Required dialysis or plasma exchange within 12 weeks prior to screening
  • Have a kidney transplant
  • Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1
  • Received intravenous glucocorticoids, >3000 mg methylprednisolone equivalent, within 4 weeks prior to screening
  • Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening
  • Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred (i.e., CD19 count > 0.01x10^9/L); received anti-tumor necrosis factor (TNF) treatment, abatacept, alemtuzumab, intravenous immunoglobulin (IVIg), belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening
  • For patients scheduled to receive cyclophosphamide treatment, urinary outflow obstruction, active infection (especially varicella zoster infection), or platelet count <50,000/μL before start of dosing
  • Participated previously in a CCX168 study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02994927). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search